MAPS Responds to Report of Progress for MDMA-assisted therapy for PTSD with FDA
August 10, 2026 — The non-profit Multidisciplinary Association for Psychedelic Studies (MAPS) today responded to an August 9 report by Psychedelic Alpha indicating that Resilient Pharmaceuticals (formerly MAPS PBC and Lykos Therapeutics) has resubmitted its new drug application (NDA) for MDMA-assisted therapy for PTSD to the U.S. Food and Drug Administration (FDA). The resubmission follows… Continue reading MAPS Responds to Report of Progress for MDMA-assisted therapy for PTSD with FDA
External link. We are not responsible for the content.
Read more ↗More From MAPS
Protected: 2026 Second Quarter — Policy & Advocacy Wrap Up
There is no excerpt because this is a protected post.
Protected: MAPS Publishes Ibogaine Investigator’s Brochure as a Free, Open-Access Resource
There is no excerpt because this is a protected post.
Psychedelic Science 2027 Speaker Submission Invites the Field to Bridge Promise and Practice
June, 25, 2026 — The Multidisciplinary Association for Psychedelic Studies (MAPS) announced the opening of speaker su...
Latest News
Why don’t some people respond to psychedelics? 5 Questions for psychologist Rachel Ham
Ham discusses doing interviews with clinical trial participants who didn’t experience substantial benefits.
Ibogaine’s Moment Has Arrived. Are We Ready to Meet It?
MAPS co-executive director Ismail Lourido Ali on what the April 2026 executive order, the Texas and Colorado funding ...
Could Ayahuasca Help Minimize the Loneliness Epidemic?
PLUS, ketamine clinics in Beirut, the Horizons conference, and trip-free psychedelics. [...] Read More... The post Co...
Scientists say just 7 days of meditation can rewire your brain
An intensive seven-day meditation retreat triggered striking changes across the brain and body, including shifts tied...
Psychedelic Policy Briefing
In this week's psychedelic policy briefing, investigative journalist Jack Gorsline unpacks a wave of state and federa...